2025 will be a very eventful year for BridgeBio. In addition to the commercial launches of Attruby in the United States, ...
Attruby (acoramidis), a near complete TTR stabilizer, has been approved by FDA to reduce cardiovascular death and ...
The price is close to the average $225,000 annual cost of Pfizer's drugs, before any discounts or rebates, although, ...
GlobalData on MSN5d
FDA approves BridgeBio’s Attruby for ATTR-CM treatmentThe US Food and Drug Administration (FDA) has approved BridgeBio Pharma’s Attruby (acoramidis), an oral transthyretin (TTR) ...
BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for ...
On a Zoom call last month from California, BridgeBio CEO Neil Kumar needled a colleague about the remote possibility of the ...
BridgeBio shares climbed by nearly 25% Monday on news its drug for a cardiac form of transthyretin amyloidosis was approved ...
We project BridgeBio's key drug candidate, Attruby (acoramidis), could achieve global sales of around $3.3 billion by 2033. Attruby is an oral drug designed to treat transthyretin amyloid ...
TipRanks on MSN8d
BridgeBio announces FDA approved Attruby for ATTR-CM patientsPharma announced that the U.S. Food and Drug Administration approved Attruby, an orally-administered near-complete stabilizer ...
PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to ...
The US Food and Drug Administration (FDA) has approved BridgeBio Pharma’s Attruby (acoramidis) to treat adults with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback